NASDAQ
08.08.25 | 19:44
2,030 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.07. | BeyondSpring reports positive results for Plinabulin combination in ICI-resistant tumors | 1 | Investing.com | ||
| 07.07. | BeyondSpring, Inc.: BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure | 2 | GlobeNewswire (USA) | ||
| 03.07. | BeyondSpring plant Jahreshauptversammlung für den 15. September | - | Investing.com Deutsch | ||
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 03.07. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | BeyondSpring reports promising phase 2 NSCLC study results | 4 | Investing.com | ||
| 03.06. | BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.05. | BeyondSpring GAAP EPS of -$0.08 | 2 | Seeking Alpha | ||
| 12.05. | BeyondSpring, Inc.: BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update | 156 | GlobeNewswire (Europe) | Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapySEED's first-in-class RBM39 degrader, reported... ► Artikel lesen | |
| 12.05. | BeyondSpring Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | BeyondSpring GAAP EPS of -$0.21 | 1 | Seeking Alpha | ||
| 27.03. | BeyondSpring Inc. Full Year Loss Declines | 1 | RTTNews | ||
| 27.03. | BeyondSpring, Inc.: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones | 168 | GlobeNewswire (Europe) | Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential... ► Artikel lesen | |
| 27.03. | BeyondSpring Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | BeyondSpring, Inc.: BeyondSpring Files 2024 Annual Report on Form 10-K | 1 | GlobeNewswire (USA) | ||
| 27.03. | BeyondSpring Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.02. | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.24 | BeyondSpring, Inc.: BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior ... | 171 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| 16.09.24 | BeyondSpring, Inc.: BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 | 182 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| 16.09.24 | BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 | 230 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BEAM THERAPEUTICS | 17,620 | 0,00 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
| JANUX THERAPEUTICS | 22,830 | 0,00 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| AVIDITY BIOSCIENCES | 46,240 | 0,00 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 32,150 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
| COGENT BIOSCIENCES | 10,960 | 0,00 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| Y-MABS THERAPEUTICS | 8,520 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 17,500 | 0,00 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,525 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| EVOTEC | 6,536 | -3,57 % | Aktien Frankfurt Ausblick: Leichte Entspannung nach US-Arbeitsmarktschock | FRANKFURT (dpa-AFX) - Nach einem von Konjunktursorgen getriebenen Rückschlag dürfte sich der deutsche Aktienmarkt am Montag zunächst leicht erholen. Der X-Dax signalisierte für den hiesigen Leitindex... ► Artikel lesen | |
| ARCELLX | 70,53 | 0,00 % | Arcellx GAAP EPS of -$0.94 beats by $0.10, revenue of $7.55M misses by $6.37M | ||
| DAY ONE BIOPHARMACEUTICALS | 6,100 | 0,00 % | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | ||
| AMYLYX PHARMACEUTICALS | 7,640 | 0,00 % | Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline | ||
| SUMMIT THERAPEUTICS | 28,675 | 0,00 % | Summit Therapeutics: Ivonescimab zeigt überlegenes progressionsfreies Überleben gegenüber Pembrolizumab | ||
| TANGO THERAPEUTICS | 6,610 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| BIONTECH | 96,55 | +0,57 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen |
BEYONDSPRING INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.